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ABSTRACT
CXCR1 and CXCR2 chemokine receptors and their ligands (CXCL1/2/3/7/8) play 
an important role in tumor progression. Tested to date CXCR1/2 antagonists and 
chemokine-targeted antibodies were reported to affect malignant cells in vitro and 
in animal models. Yet, redundancy of chemotactic signals and toxicity hinder further 
clinical development of these approaches. In this pre-clinical study we investigated 
the capacity of a novel small molecule dual CXCR1/2 inhibitor, Ladarixin (LDX), to 
attenuate progression of experimental human melanomas. Our data showed that LDX-
mediated inhibition of CXCR1/2 abrogated motility and induced apoptosis in cultured 
cutaneous and uveal melanoma cells and xenografts independently of the molecular 
defects associated with the malignant phenotype. These effects were mediated by 
the inhibition of AKT and NF-kB signaling pathways. Moreover, systemic treatment 
of melanoma-bearing mice with LDX also polarized intratumoral macrophages to M1 
phenotype, abrogated intratumoral de novo angiogenesis and inhibited melanoma 
self-renewal. Collectively, these studies outlined the pre-requisites of the successful 
CXCR1/2 inhibition on malignant cells and demonstrated multifactorial effects of 
Ladarixin on cutaneous and uveal melanomas, suggesting therapeutic utility of LDX 
in treatment of various melanoma types.
INTRODUCTION
Malignant melanoma expresses and secretes 
various CXC chemokines, including CXCL1, CXCL2, 
CXCL3 (GRO family chemokines) and CXCL8 (IL-8). 
These molecules render the tumor microenvironment 
and facilitate progression and metastatic dissemination 
of melanomas via autocrine and paracrine activation of 
CXCR1 and CXCR2 chemokine receptors (reviewed 
in [1]). Studies on spontaneously immortal mouse 
melanocytes showed that stable expression of GRO 
family members enhances colony-forming abilities of 
the melanocytes, whereas antibody-mediated blocking 
of these chemokines inhibits experimental melanoma 
growth [2-4]. Elevated expression of CXCL8 (IL-8) 
was also associated with the intratumoral endothelial 
cell chemotaxis, neovascularization and angiogenesis in 
vitro and in vivo [5]. Up-regulated expression of IL-8 and 
CXCL1 were also associated with NF-kB transcription 
factor activity in cultured melanoma cells [6, 7]. All of 
these observations reinforce the concept that Gro-family 
chemokines and CXCL8 (IL-8) act as paracrine and 
autocrine mediators on melanoma growth and progression. 
The biological effects of these chemokines are mediated 
through two G protein-coupled receptors, CXCR1 and 
CXCR2 [8]. Engagement of these receptors induces 
intracellular signaling transmitted through heterotrimeric 
G proteins with Gαi being a predominant G protein 
coupled to this receptor family [9]. CXCR1 and CXCR2 
receptors also exhibit a markedly distinct ligand binding 
pharmacology: CXCR1 is predominantly activated by 
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CXCL8 and CXCL6, whereas CXCR2 could be activated 
by CXCL1-3 and 5-8 [10]. Expression of both receptors 
and multiple ligands by melanoma present certain 
challenges in designing therapeutic strategies to attenuate 
the effects of these chemokines [11]. 
To date, several strategies were employed to 
reduce/inhibit intracellular signaling mediated by CXCR1 
and CXCR2 receptors. A number of ligand-blocking 
antibodies and small molecular weight antagonists of these 
chemokines, particularly CXCL8, were developed and 
tested [11]. Although blocking of individual chemokines 
provided certain benefits in treatment of acute and chronic 
inflammation [12], this approach may not provide desired 
outcome in treating neoplasms due to the redundancy of 
chemotactic signals. 
Further search for effective competitive antagonists 
led to the identification of a number of compounds that can 
block CXCR1/2 receptor [11]. An advanced development 
program was originated by Dompé Farmaceutici 
with Reparixin, the first non-competitive allosteric 
CXCR1/2 inhibitor that is currently under active clinical 
investigation for the prevention of graft loss in pancreatic 
islet transplantation (Phase 3) and treatment of metastatic 
triple negative breast cancer (Phase 2). Ladarixin (LDX) 
is a second generation dual CXCR1/2 inhibitor due to 
its > 100 fold higher affinity for the CXCR2 receptor 
and improved pharmacokinetic properties that make 
it suitable for oral chronic administration. Ladarixin 
inhibits human polymorphonuclear leukocyte (PMN) 
migration to CXCL8 (IC50 at 0.7 nM) in vitro, and 
prevents PMN infiltration and tissue damage in several 
models of IR injury in vivo [13]. LDX is well-tolerated 
at all studied doses and showed excellent safety profile in 
human subjects in current clinical trials for the treatment 
of Type 1 diabetes (unpublished data). In this study, we 
demonstrated that LDX attenuates progression of different 
melanoma types in vivo via inhibition of cell cycle 
progression and motility, blocking of the pro-survival 
intracellular signals and induction of apoptosis, alteration 
of the intratumoral recruitment of the endothelial cells and 
de novo angiogenesis, and hindering of the melanoma self-
renewal mechanisms.
RESULTS
Analysis of CXCL1/2/3/8 chemokines and 
CXCR1/2 receptors in primary melanoma cells
Considering heterogeneity of human melanomas, 
various molecular defects associated with discrete types 
of this neoplasm, and variable patterns of chemokine/
receptor expression, we examined several primary human 
melanoma cell lines characterized by different molecular 
defects for the expression of CXCR1/2 and their ligands 
(CXCL1/8). Cutaneous melanoma cells expressing mutant 
BRAFV600E(WM164, WM115, WM873) [14, 15], cells 
with non-defined molecular defect expressing BRAFG464E 
and KRASG12D (C8161) [16] and uveal melanoma cells 
harboring an activating mutation in GNAQQ209P (UM001) 
[17] were used for this assessment. RT-PCR analysis 
showed that CXCL1 and CXCL8 were differently 
expressed in the analyzed cells with the overall lowest 
expression in WM164 and WM115 and the highest in 
WM873-1and in C8161 melanoma cells (Figure 1A). 
Secretion of chemokines from these cells and from primary 
dark- and light-pigmented primary human melanocytes 
(1256b and 1603c, respectively) assessed by chemokine 
antibody array showed that levels of CXCR1/2 ligands 
were higher in all but one (WM164) melanoma lines as 
compared to melanocytes (Figure 1B, 1C). Secretion 
of CXCL8 was consistently elevated in all malignant 
cells (Figure 1B, 1C). Expression CXCR1/2 receptors 
was also examined. RT-PCR and Western Blot analyses 
confirmed expression of both receptors in malignant cells 
with on average 2 times higher expression of CXCR2 
as compared to CXCR1 (Figure 1A). However, FACS 
analysis demonstrated that CXCR1 and CXCR2 were not 
uniformly present on the surface of the malignant cells. 
More than 50% of WM164 and UM001cells have these 
receptors consistently present on the cell surface, whereas 
only small populations of WM873, C8161and WM115 
were recognized as receptor-positive (Figure 1D). FACS 
also revealed the existence of a discrete population of the 
CXCR1/2 cell surface-positive malignant cells (Figure 
1D). These observations were confirmed by the direct 
(Figure 1E) and indirect (Supplementary Figure S1A) 
immunofluorescent detection of the receptors showing that 
WM115 and WM873 cells contained receptor-positive and 
negative populations, whereas a majority of the WM164 
and UM001 were positive for both receptors on the cell 
surface (Figure 1E, Supplementary Figure S1A). 
Ladarixin-mediated inhibition of melanoma 
motility, adhesion and survival in vitro
Considering involvement of the CXCR1/2 signaling 
in migration, the effect of the LDX on motility of 
melanoma cells was examined using in vitro migration/
scratch assay. The presence of LDX in normal culture 
media for 24 h led to an inhibition of melanoma cell 
motility (Figure 2A, 2B). A more profound inhibition 
was observed on cells with higher cell surface CXCR1/2 
and lower expression of their ligands (WM164, WM115, 
and UM001 lines). Treatment of these cells with LDX 
led to 10-fold inhibition of cell migration. Exposure of 
WM873 and C8161 cells with lower cell surface receptor 
expression to LDX led to a 2-fold decrease of motility 
(Figure 2B).
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In these experiments, we observed an increased 
number of dislodged cells in the presence of LDX. This 
sparked further assessment of cellular attachment and 
adhesion by the modified McClay substrata binding assay 
as described in our prior studies [18]. The presence of the 
LDX during plating and for additional 4 h did not alter the 
adhesion of the LDX-treated and control cells, although 
a slight reduction in a number of adherent UM001 cells 
was observed (Table 1). Exposure of melanoma cells 
to LDX for 3 days affected mostly WM164 cells with 
3 times more cells remaining on plastic substrata when 
cultured in the absence of the LDX. Exposure of cells 
to LDX for an additional 2 days had a more detrimental 
effect on all cell lines. On average, 3 times more cells 
remained attached to plastic substrata when cultured in 
the absence of LDX (Table 2). These findings suggest 
that LDX-mediated blocking of the CXCR1/2 signaling 
affects expression of the adhesion molecules or leads to 
the cell death and detachment. Therefore, expression of 
cadherins was analyzed by Western blot under referenced 
above conditions. High expression of epithelial cadherin 
(E-cadherin) was detected only in WM35 melanoma cells 
isolated from primary (radial growth phase) lesion. In 
cells from more advanced lesions (vertical growth phase 
or metastatic), a substantial reduction or absence of this 
cadherin was observed (Figure 2C). N-Cadherin, which 
is commonly associated with invasion and metastasis of 
neoplasms, was detected in all cell lines isolated from local 
and distal metastatic lesions with the lowest expression 
in the WM35 cell line. P-cadherin, whose expression is 
associated with poorly differentiated carcinomas [19, 20], 
was barely detectable in all examined cells. Treatment of 
cells with LDX did not alter expression of these cadherins 
(Figure 2C), suggesting that progressive loss of attached 
LDX-treated cells could be attributed to apoptosis. Based 
on the in situ cell death detection (TUNEL) assay, on 
average, about 3% of all control cells were identified as 
apoptotic whereas LDX treatment increased apoptosis up 
to 10% for C8161 and WM873 cells, 25 % for WM 164 
and WM115 cells, and up to 40% for UM001 (Figure 2D, 
2E). 
Given that NF-kB supports survival of the 
malignant cells via Bcl-2/Bcl-XL-dependent pathway 
and augments transcription of CXCR1/2 ligands [1], we 
investigated whether LDX treatment abrogates NF-kB 
expression and/or activation. To assess whether LDX-
mediated CXCR1/2 blocking affects NF-kB activity, we 
generated several melanoma cell lines stably expressing 
NanoLuc® luciferase under the control of the NF-κB 
response elements. Exposure of these cells to LDX (1 
ηM, 100 ηM, 1µM) for 24 h in vitro led to reduction of 
NanoLuc in all examined cells confirming LDX-mediated 
down-modulation of the NF-kB activity (Supplementary 
Figure S1B). Exposure of all malignant cells to LDX for 
72 h led to an intracellular re-distribution of NF-kB and 
its accumulation in the cytoplasm. It was particularly 
evident in WM164 and UM001 cells (Figure 2F). Western 
Blot analysis with serine536-phosphorylated NF-kB-
specific antibodies confirmed the reduction of the NF-kB 
activation and nuclear translocation in LDX-treated cells. 
It was most prominent in WM35, WM164, WM115, and 
UM001, and less pronounced in C8161 cells (Figure 2C). 
As Akt plays an important role in controlling the balance 
between survival, apoptosis and NF-kB activation [21], 
we also assessed the status of this serine-threonine kinase. 
Based on the Western Blotting, treatment of the cells with 
LDX did not alter the expression of the AKT but markedly 
reduced its phosphorylation on Thr308 in all examined 
cell lines (Figure 2C). Persistent activation of STAT3 
has been shown to mediate several oncogenic features in 
many types of cancers, including melanoma [22]. CXCL8 
(IL-8) signaling has been implicated in STAT3 activation 
and nuclear translocation [23], suggesting that inhibition 
of CXCR1/2 may also lead to the inhibition of STAT3 
in melanoma cells. However, Western Blot analysis 
showed a relatively low basal level of STAT3 expression 
in all malignant cells and insignificant changes in STAT3 
phosphorylation after LDX treatment (Figure 2C).
Collectively, these in vitro studies demonstrated 
that exposure of malignant cells to LDX resulted in 
down- modulation of cell cycle progression, motility, Akt 
and NF-kB phosphorylation-dependent activation, and 
induction of apoptosis independently of molecular defects 
underlying tumorigenic phenotype. These studies also 
demonstrated that LDX-mediated inhibition of CXCR1/2 
has the most profound effect on melanoma cells with 
higher level of cell-surface receptors and lower secretion 
of ligands (eg. WM164), and only partial effect on cells 
with lower number of cell surface receptors and higher 
secretion of ligands (eg. C8161). 
Ladarixin-mediated inhibition of melanoma 
xenografts in vivo
To evaluate the extent of LDX-mediated melanoma 
inhibition in vivo and better define the underlying 
molecular mechanisms, 4 different human melanoma 
cell lines characterized by various levels of cell surface 
CXCR1/2, ligands secretion and distinct molecular defects 
(WM164V600E,C8161, UM001Q209P and UM004Q209L) were 
inoculated into nude athymic mice. Starting from day 10 
after inoculation, when lesions reached about 50 mm3 
(~4x4x3 mm), experimental groups (n = 10 per group) 
were receiving LDX via intraperitoneal (IP) injection 
once a day at 15 mg/kg. Control animals were receiving 
saline. Consistent with our in vitro studies, systemic 
administration of LDX had limited effect on growth of 
C8161 melanoma lesions but significantly inhibited 
growth of WM164, UM001 and UM004 melanomas 
(Figure 3A). All LDX-treated lesions were visually less 
vascularized (particularly UM001) compared to untreated 
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controls (Figure 3A). 
Histological examination showed that all lesions 
from LDX-treated animals contained apoptotic regions 
with elevated leukocytic infiltrate (Figure 3B). The largest 
apoptotic regions occupying on average 2/3 of the entire 
tumor volume were detected in LDX-treated C8161 
lesions. These regions were characterized by the presence 
of TUNEL-positive melanoma cells and a large number 
Figure 1: Analysis of chemokines and receptors in primary melanoma cells. A. RT-PCR and Western Blot analyses of CXCL1/8 
chemokines and CXCR1/2 receptors expression in different melanoma cell lines (as indicated on the panel). B. Representative images of 
the antibody array analysis used for the detection of the secreted chemokine. Blue frame - CXCL1/2/3 (Gro family) chemokines; Green 
frame - CXCL1; Red frame - CXCL8. C. Quantitation of chemokines secretion by melanoma cells relative to light-pigmented (1603c) 
and dark-pigmented (1256b) melanocytes. Data collected from 3 independent measurements and presented as a fold difference ± SD. Cell 
lines are indicated on the panel. D. Analysis of cell-surface CXCR1/2 in melanoma cells by FACS. Cell lines and receptors are indicated 
on the histograms. Calculated percentage of receptor-positive cells indicated below the histograms. E. Detection of CXCR1/2 receptors by 
fluorescently-labeled receptor-specific antibodies. Red - CXCR1/2 receptors, Blue - DAPI nuclear staining. 
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of CD11b+ leukocytes (Figure 3C, 3D). Considering a 
dual role of the tumor-infiltrating CD11b+ macrophages 
that may prevent (M1 macrophages) or promote (M2 
macrophages) tumorigenesis [24], expression of 
nitric oxide synthase 2 (iNOS) as a marker for the M1 
macrophages was analyzed. Majority of the intratumoral 
CD11b+ cells in control lesions did not express iNOS 
(Figure 3C, 3D). On the contrary, more than 60% of 
tumor-infiltrating CD11b+ cells in LDX-treated lesions 
were iNOS-positive (Figure 3C, 3D). 
Considering apoptosis as a primary mechanism 
involved in LDX-mediated melanoma cell death, we 
examined the status of the key apoptotic markers in 
LDX-treated and control lesions. Concurrent detection 
of caspase-cleaved PARP and cytokeratin 18 confirmed 
apoptotic mechanism of malignant cell death in all LDX-
treated animals (Figure 3C, 3D). Quantitation of apoptotic 
cells showed that more than 60% of cells in the affected 
regions were positive for both apoptotic markers. A 
substantial reduction of the proliferating Ki-67+ cells and 
increased number of the cleaved cytokeratin 18 (M30+) 
cells were also observed in non-apoptotic regions (Figure 
3C). Inverse correlation between Ki-67+ proliferating and 
M30+ apoptotic cell was most distinct in WM164 treated 
melanomas (Figure 3C, 3D). Immunofluorescent detection 
of Ki-67 and gp-100 melanoma differentiation antigen 
confirmed LDX-mediated inhibition of proliferation in 
malignant cell in non-apoptotic tumor regions (Figure 3C). 
Figure 2: Analysis of melanoma cell motility and apoptosis. A. Micrographs illustrating LDX-mediated inhibition of melanoma 
cell motility assessed by scratch assay. Cell lines and conditions indicated on the micrographs. Scale bar – 100 mm. Introduced scratches are 
outlined by puncture lines. B. Quantitation of LDX treated and control melanoma cell migration. Data is presented as an average number 
of cells migrated into the scratch (10 independent microscopic fields) ± SD. Statistical significance (p-value) was calculated using 2 tailed 
t-test is shown above the columns.  Percentage of migrated LDX-treated cells relative to mock-treated control is shown below the columns. 
C. Western blot analysis of adhesion and signaling molecules in representative LDX-treated and control melanoma cells (indicated above 
the panels). Analyzed molecules are shown to the right of the panels. Phosphorylated NF-kB, STAT3 and AKT are marked as P-proteins. 
Beta actin was used as loading control. D. Microscopic analysis of apoptosis in control and LDX-treated melanoma cells by TUNEL 
assay. Cell lines, treatment and calculated percentage of apoptotic cells shown on representative images. E. Quantitation of apoptosis as 
determined by the TUNEL assay in all investigated melanoma cell lines (indicated below the columns). Data is presented as average of 3 
independent experiments ± SD. Five random microscopic fields were used for each treatment condition/cell line to calculate percentage.  F. 
Indirect immunofluorescent analyses of NF-kB nuclear translocation/activation in control and LDX-treated representative melanoma cells. 
Treatment and cell lines are indicated on the panels. Red – Nf-kB, Green – LaminA/C (outlines nuclear membrane).  
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To better define molecular mechanisms involved in 
LDX-mediated inhibition of melanoma in vivo, NF-kB and 
STAT3 in control and LDX-treated lesions were examined 
by the indirect immunofluorescence. This analysis 
demonstrated preferential nuclear localization of NF-kB in 
the control and cytoplasmic localization in treated lesions 
(Figure 4A). Detection of STAT3 in control and LDX-
treated lesions did not reveal any significant differences, 
although a more pronounced nuclear staining of the STAT3 
was detected in controls. These observations were further 
confirmed by Western blot analysis. A reduction of the 
Ser536-phosphorylated NF-kB and Thr308-phosphorylated 
Figure 3: LDX-mediated inhibition of melanoma xenotransplants in vivo. A. Graph of the lesions at 30 days showing tumor 
development in LDX-treated and control mice. Data is presented as a mean tumor volume (mm3) ±SD. Statistical significance is presented 
as p-value (shown of the graph). B. Representative micrographs of the H&E stained sections of the control and LDX treated lesions 
showing the presence of the apoptotic regions (dotted line) and leukocytic infiltrates (black arrows). C. Indirect immunofluorescence-based 
characterization of LDX-treated and control tumors. As all mock-treated lesions were similar, micrographs of the control C8161 lesions 
are shown as representative controls. Detected antigens are shown to the left of the panels in corresponding colors. Blue - DAPI nuclear 
staining. Scale bars: 10 µm (2, 3, and 5th rows from the top) and 100 µm (1, 4th rows from the top). D. Quantitation of antigen-positive cells 
shown on panel C. Data is presented as an average percentage of positive cells per microscopic field ± SD. 
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AKT and Tyr705-phosphorylated STAT3 was observed in 
all LDX-treated lesions (Figure 4B), suggesting that LDX-
mediated CXCR1/2 inhibition attenuates NF-kB/AKT 
activation making malignant cells susceptible to apoptosis 
and reducing their proliferative capacities.
Previous studies demonstrated that CXCR1/2 
receptors are expressed by microvascular endothelial 
cells and that secretion of CXCR1/2 ligands by 
melanoma enhances de novo angiogenesis [25]. Indirect 
immunofluorescent detection of the CD31+ intratumoral 
blood vasculature demonstrated a drastic reduction 
of endothelial cell recruitment and formation of the 
intratumoral blood vessels in all examined LDX-treated 
lesions. Lack of the intratumoral angiogenesis was 
particularly evident in peri-apoptotic regions of the LDX-
treated tumors, where blood vessels were not detected 
at all (not shown). A reduction CD31+ blood vessels in 
non-apoptotic regions of all LDX-treated lesions was 
apparent (Figure 4A) and confirmed by the assessment of 
microvessel density (Table 3). 
Several recent studies suggested that so called 
tumor-initiating cells responsible for melanoma self-
renewal display high aldehyde dehydrogenase (ALDH) 
activity and enhanced tumorigenicity over ALDH-negative 
cells [26, 27] . Considering a potential correlation between 
CXCR1/2 expression and ALDH activity reported in 
breast carcinoma [28, 29], we tested how LDX treatment 
affects ALDH+ melanoma cells. In all cultured cells, 
independently of the tumorigenic mutation, about 4% of 
cells were ALDH-positive whereas in xenotransplants it 
was increased up to 10% in the lesions (Figure 5A, 5B). 
Treatment of tumor-bearing mice with LDX led to an 
inhibition of ALDH expression in non-apoptotic regions 
of the lesions where ALDH+, HMB45+ (gp100+) malignant 
cells were rarely detected (Figure 5A, 5B, 5C). Percentage 
of these cells decreased on average 4 times for UM001, 8 
times for WM164, and 10 times for C8161 (Figure 5C). 
Concurrently, a higher percentage of the ALDH+ cells was 
detected in non-proliferating, apoptotic, M30+ regions of 
LDX treated lesions (Figure 5B, 5C). In fact, all ALDH+ 
cells were also positive for caspase-cleaved cytokeratin 
18 (Figure 5B). Collectively, these data demonstrated that 
treatment of melanoma-bearing mice with LDX leads to 
the inhibition of ALDH in non-apoptotic malignant cells 
and its induction in cells undergoing apoptosis. 
DISCUSSION
Previous studies demonstrated that different CXCR1 
and CXCR2 antagonists can block these receptors 
inhibiting inflammation and tumor growth in various 
animal models. For example, G31P, an IL-8 analog, 
was shown to block neutrophil infiltration, pyrexia, and 
pulmonary vascular pathology in endotoxemic animals 
Table 1: Melanoma cell adhesion at plating
Ladarixin WM164 C8161 TSUM1 Time
Ldx- 0.366±0.085 0.641±0.073 0.126±0.034 4hr
Ldx+ 0.288±0.058 0.518±0.063 0.144±0.038 4hr
Ldx- 0.349±0.064 0.521±0.0532 0.394±0.048 3hr
Ldx+ 0.221±0.074 0.435±0.034 0.313±0.058 3hr
Ldx- 0.310±0.053 0.524±0.041 0.338±0.069 2hr
Ldx+ 0.221±0.051 0.483±0.049 0.322±0.055 2hr
Ldx- 0.333±0.069 0.519±0.061 0.346±0.066 1hr
Ldx+ 0.219±0.054 0.418±0.044 0.301±0.034 1hr
Data is presented as optical density measured at 570 nm (OD A570) reflecting attached cells.
Table 2: Assessment of cellular attachment to the plastic substrata (ODA570)
Time Ladarixin WM164 C8161 TSUM1
5 Days LDX - 0.178±0.02 0.175±0.012 0.156±0.012
5 Days LDX + 0.048±0.017 0.049±0.011 0.066±0.013
4 Days LDX - 0.192±0.014 0.17±0.014 0.155±0.012
4 Days LDX+ 0.05±0.013 0.074±0.017 0.081±0.017
3 Days LDX - 0.199±0.018 0.17±0.012 0.182±0.013
3 Days LDX + 0.059±0.012 0.185±0.012 0.157±0.015
Data is presented as optical density measured at 570 nm (OD A570) reflecting density of the attached cells.
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[30, 31]. SCH-527123 and SCH-479833, dual CXCR1/2 
and CXCR2 antagonists, were shown to inhibit migration 
and proliferation of A375SM melanoma cells [32]. SCH-
527123 was described as a potent inhibitor of CXCR1- 
(IC50 = 41 nM) and CXCR2 (IC50 = 3 nM) mediated 
chemotaxis with high affinity [33]. It was shown to 
inhibit neutrophil recruitment, mucus production and 
goblet cell hyperplasia in animal models of pulmonary 
inflammation [34]. The potential therapeutic effect of 
SCH-527123 in the treatment of chronic pulmonary 
diseases has been widely investigated in several clinical 
studies, but the lack of evident long-term clinical benefit 
and associated neutropenia led to discontinuation of its 
clinical development [35-37]. In this study, we assessed 
therapeutic aspects of a novel, dual small molecule 
CXCR1/2 inhibitor, Ladarixin, to attenuate development 
and progression of human melanomas characterized 
by different molecular defects. Ladarixin is orally 
bioavailable, potent and selective non-competitive 
allosteric CXCR1/2 inhibitor that binds an allosteric 
pocket of the trans-membrane region of both receptors. 
The allosteric action results in a dramatic reduction of 
CXCR1 (IC50 = 0.9 nM) and CXCR2 (IC50 = 0.8 nM) 
mediated chemotaxis in the absence of any significant 
influence on ligand/receptor binding [38]. Ladarixin 
was also effective in decreasing CXCL8-induced 
Figure 4: Analysis of NF-kB, STAT3, AKT and angiogenesis in control and LDX-treated lesions. A. Indirect 
immunofluorescent analysis of NF-kB, STAT3 and CD31 (as a marker of angiogenesis de novo) in control and LDX-treated lesions. As 
all mock-treated lesions were similar, micrographs of the control C8161 lesions are shown as representative controls. Detected antigens 
(in corresponding colors) are show to the left of the panels. Blue - DAPI nuclear staining. Cell lines and treatments are shown above the 
panels. Scale bar - 10 µm. B. Western blot analysis of NF-kB, STAT3, AKT phosphorylation in control and LDX-treated lesions. Cell lines 
and treatments are shown above the panels. 
Oncotarget14436www.impactjournals.com/oncotarget
polymorphonuclear leukocyte infiltration in several animal 
models without a significant dose-related reduction in 
systemic neutrophil counts. Confirmation of this last 
observation from Phase 1 clinical studies suggests that 
allosteric modulation may represent a promising approach 
to the design of safe and well-tolerated drugs acting at 
chemokine receptors.
Limited number of reports on targeted inhibition of 
Gro family chemokines, CXCL8 (IL-8) and their receptors 
(CXCR1 and CXCR2) in various tumor models including 
melanomas, suggested a potential applicability of these 
approaches for tumor growth inhibition (11). However, 
redundancy of chemotactic signals presents a significant 
challenge in designing therapeutic strategies to attenuate 
the effects of CXCR1/2 signaling on melanoma cells 
and tumor microenvironments, and the pre-requisites 
for the successful treatment remain undefined. Presented 
here analysis demonstrated that melanoma cells secrete 
different levels CXCL1 and CXCL8 and rather high 
levels of CXCL2 and CXCL3 chemokines (Figure 
1). Concurrently, tumor cells express both CXCR1/2 
receptors. FACS analysis revealed the existence of 
Figure 5: Assessment of tumor-initiating ALDH+ melanoma cells in vitro and in vivo. A. Indirect immunofluorescent detection 
of ALDH+ melanoma cells in vitro and in vivo. Detected antigens (in corresponding colors) are shown to the right of the panels. Scale 
bar - 10 µm. B. Indirect immunofluorescent detection of the ALDH+ cells in non-proliferating (Ki-67-negative), apoptotic (M30-positive) 
cells in LDX-treated lesions. Scale bar - 100 µm. C. Quantitation of ALDH+ cells in control cultured cells and non-apoptotic regions of the 
LDX-treated lesions (Panel A). Data is presented as average percentage of ALDH+ cells per microscopic field ± SD.
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distinct populations of receptor-positive and receptor-
negative cells in otherwise homogeneous malignant cell 
cultures (Figure 1D). This analysis also demonstrated 
that despite a rather high level of CXCR1/2 expression 
in some melanoma cells (eg. WM873 and C8161), only 
a small percentage of cells had receptors on the cell 
surface, whereas other cells (eg. WM164 and UM001) 
had a consistently high number of receptor-positive cells. 
These observations suggest that in malignant cells with 
high secretion of the autocrine chemokines and high level 
of CXCR1/2 expression (as in WM873 and C8161) a 
rapid binding and internalization of the ligand/receptor 
complexes may lead to the “removal” of the receptors 
from the cell surface, as previously observed for CXCR4-
CXCL12 [39]. These findings also suggest that CXCR1/2 
blocking may have limited direct effect on melanoma cells 
with the lower number of cell surface receptors and high 
levels of autocrine chemokines. 
Consistent with the prior data obtained on A375SM 
cells using SCH-527123 inhibitor (29), LDX treatment 
inhibited melanoma cells motility. However, our analysis 
clearly demonstrated that LDX-mediated inhibition 
of motility, proliferation, AKT and NF-kB activation 
and induction of apoptosis directly correlated with the 
percentage of CXCR1/2-positive cells. Thus, WM164, 
WM115 and UM001 cells were more susceptible to the 
LDX treatment than WM873 or C6181 cell. Importantly, 
treatment of different melanoma cells in vitro with 1µM 
LDX was more effective than treatment of A37SM with 
250 µM SCH-527123 (29).
Consistent with the in vitro data, treatment of the 
experimental melanoma-bearing mice with LDX (15 mg/
kg) led to the inhibition of tumor growth independently of 
the molecular defects underlying tumorigenic phenotype. 
Thus, statistically significant inhibition of BRAFV600E 
WM164, GNA11Q209L UM001 and GNAQQ209P UM004 
melanomas was observed (Figure 3). These observations 
support the notion that malignant cells with higher cell-
surface CXCR1/2 expression and lower expression the 
ligands (e.g. WM164) are more susceptible to LDX 
than cells with lower sell surface receptors (e.g. C8161). 
Although, treatment of C8161 melanoma-bearing mice 
with LDX did not alter outgrowth of the intradermal 
tumors, normalized rate of apoptosis and inhibition of 
proliferation were similar in all LDX-treated lesions 
(Figure 3D) and C8161 lesions contained large apoptotic 
regions approaching 2/3 of the entire tumor volume. Such 
discrepancy could be explained by faster proliferation of 
the C8161 cells, higher expression of the CXCR1/2 ligands 
that cause rapid internalization of the receptors and higher 
microvascular density, particularly, in the periphery of the 
established C8161 tumors. Together with the inhibition 
of AKT and NF-KB activation/phosphorylation in vitro 
(Figure 2) and in vivo (Figure 4A), our data indicate that 
LDX-mediated induction of apoptosis in malignant cells 
is associated with down-modulation of the AKT/NF-kB-
mediated pro-survival signals. Comparison of our in vivo 
data with previous findings obtained using SCH-527123 
at 100 mg/kg dose [32] showed that systemic treatment 
of tumor-bearing mice with LDX is more effective, as 
reflected by the inhibition of melanoma cell proliferation, 
angiogenesis and induction of apoptosis (Figure 3D, 
Figure 4). 
Moreover, we observed that apoptotic regions in 
LDX-treated lesions were heavily infiltrated with CD11b+ 
TAMs characterized by the uniform expression of the 
iNOS, a well-known maker of the M1 macrophages with 
tumoricidal activity. These findings suggest that LDX 
treatment may directly or indirectly affect polarization 
of the TAMs contributing further to the inhibition of the 
neoplasms. 
Previous studies demonstrated that CXCR1/2 
expressed on the surface of the blood endothelial cells play 
an important role in the recruitment and the intratumoral 
de novo angiogenesis [5, 25]. Our analysis demonstrated a 
significant reduction of the intratumoral CD31+ endothelial 
cells and blood vessels in LDX-treated tumor-bearing mice 
(Figure 4). These findings also indicate that LDX-mediated 
alteration of the melanoma-supporting microenvironment 
additionally attenuates tumor progression and may further 
contribute to the induction of apoptosis of the malignant 
cells (eg. C8161). 
Presented here studies also support the notion that 
LDX treatment prevents “rejuvenation’ of the tumors by 
affecting cells with enhanced tumorigenic capabilities, 
so called melanoma-initiating cells. Several recent 
studies demonstrated that a distinct population of human 
melanoma cells with high ALDH activity is responsible 
for tumorigenesis and tumor self-renewal [26, 27] and 
that silencing of ALDH by shRNA leads to melanoma 
cell cycle arrest, apoptosis, decreased cell viability in 
vitro and reduced tumorigenesis in vivo [27]. Therefore, a 
decrease of the ALDH+ melanoma cells in non-apoptotic 
regions of all LDX-treated tumors (Figure 5) could 
Table 3: LDX-mediated inhibition intratumoral microvessel density (MVD)
Cells MVD (± SD) - // + LDX % inhibition t-test
C8161 22±4  // 8±3 62 <0.05
WM164 18±4  //  4±2 78 <0.05
UM001 15±2  //   4±2 73 <0.05
UM004 14±2  //   5±2 65 <0.05
Immunofluorescent staining for microvessel using anti-CD31 was analyzed as described in Materials and Methods. MVD was 
quantitated on 10 independent microscopic fields per sample.
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be directly related to the reduced tumor-regenerating 
capacity and abrogation of melanoma self-renewal 
mechanism. Although we identified a higher percentage 
of the ALDH+ cells in the apoptotic regions, ALDH 
expression coincided with the caspase-mediated cleavage 
and release of the cytokeratin18 fragments (Figure 5), the 
hallmark of the intermediate stage of apoptosis. Apoptosis 
is a tightly regulated process that inevitably leads to 
structural and biochemical changes and eventually to cell 
death and phagocytosis. Although, ALDH is an enzyme 
that detoxifies aldehydic products generated by reactive 
oxygen species and enhances cell survival, it is unlikely 
that ALDH expression in apoptotic cells may reverse 
mid-apoptosis. This notion is indirectly supported by the 
accumulation of the macrophages in apoptotic regions that 
phagocytose dead melanoma cells.
Collectively, presented here data demonstrate that 
Ladarixin, a dual CXCR1/2 small molecule inhibitor, 
has a multifactorial effect on melanomas in vitro and in 
vivo independently of the genetic defects underlying 
tumorigenic phenotype. These effects include inhibition of 
melanoma cell motility, NF-kB and AKT-mediated pro-
survival signaling, increased apoptosis, down-modulation 
of pro-angiogenic signaling and formation of the 
intratumoral microvasculature de novo, polarization of the 
intratumoral macrophages to M1 tumoricidal phenotype, 
and blocking of the ALDH+ cell-dependent melanoma 
self-renewal mechanism. These pre-clinical findings 
demonstrated therapeutic utility of LDX for the inhibition 
of various melanomas independently of the tumor-driving 
mutations. 
MATERIALS AND METHODS
Cell lines and culture
All WM and C8161 primary melanoma cell lines 
were kindly provided by Dr. M.Herlin (Wistar Institute, 
Philadelphia PA). Cell were cultured in MCDB164/L15 
media (4/1) supplemented with 2% Fetal Bovine Serum 
(FBS), Bovine insulin, and calcium chloride. Uveal 
melanoma lines UM001 and UM004 characterized by 
the activating mutations in GNAQQ209P and GNA11Q209L 
were provided by Dr. T. Sato (Thomas Jefferson 
University, Philadelphia PA) and cultured in RPMI1640 
media supplemented with 10% FBS, β-mercaptoethanol, 
penicillin and streptomycin. Derivative melanoma cell 
lines expressing Nano luciferase under the control of 
the NF-kB response elements were generated by stable 
transfection of the parental cells with pNL3.2 NF-kB-
RE [NlucP NF-kB-RE Hygro] (Promega, Madison, WI). 
Primary human melanocytes were kindly provided by Dr. 
Z. Abdel-Malek (University of Cincinnati, Cincinnati, 
OH) and cultured in Epilife culture media with TPA-free 
supplements (Thermo/Fisher, Grand Island, NY).
Reagents
Ladarixin, a dual CXCR1 and CXCR2 inhibitor 
was provided by Dompé Farmaceutici SpA, Via Campo 
di Pile, L’Aquila, Italy. LDX was prepared fresh daily by 
dissolving in culture media (in vitro experiments) or in 
PBS (in vivo experiments) to desired concentration. 
Analysis of chemokines secretion
Chemokine-targeted antibody-based array (Ray 
Biotech, Norcross, GA) was used for analysis of 
melanocytic cell-derived secreted chemokines as devised 
by the manufacturer. Normalization and quantitation of 
chemokine secretion was done using array-specific Ray 
Biotech Analysis Tool.
FACS
Fluorescently-labeled CXCR1 and CXCR2-specific 
antibodies for FACS were from BioLegend (San Diego, 
CA). Cell sorting was done on Guava EasyCyte system 
and analyzed using InSyte Software (Millipore, Billerica 
MA). 
In vitro migration assay
Cells were plated at sub-confluent density onto 
6-well plates and grown to confluence. Then, a 0.5 mm 
scratch was introduced and cells were allowed to migrate 
into the area for 24 h in the presence or absence of LDX 
(1x10-5 M). Ten independent images were taken from each 
cell line/condition and cells migrated into the scratch, 
were enumerated. 
Melanoma cell adhesion and attachment
Different melanoma cells were plated onto 96 well 
plates and allow attaching to plastic substrata for 1, 2, 3 
and 4 h or kept up to 5 days in the presence or absence of 
LDX (1x10-5 M) in culture media. At indicated time points, 
cells were fixed in 3% formaldehyde and stained with 
0.1% crystal violet. After washes, plates were scanned 
at 570 nm on Bio Tech FL600 plate reader (Biotech 
Inc., Richmond, VA). Results were obtained from three 
independent experiments, three wells for each experiment.
Assessment of apoptosis
Apoptosis was assessed using In Situ Cell Death 
detection kit (TUNEL assay) (Roche Bioscience, 
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Indianapolis, IN). Quantitation was done on images of 5 
random microscopic fields per cell line per treatment. 
Treatment with LDX in vitro and in vivo
For all in vitro experiments, unless otherwise 
stated, LDX was dissolved in phosphate buffered saline 
(PBS), filter-sterilized and used at 1x10-5 M. For in vivo 
treatment of tumor-bearing animals, LDX was dissolved 
in PBS, filter-sterilized and used at 15 mg/kg. LDX was 
administered via intraperitoneal (IP) injection once a day, 
every day, for the duration of the experiment. The dose 
was abopted from prior experiments on the 1st generation 
of CXCR1 inhibitor, Reparixin [40]
Animal treatment
Eight cohorts of NCrNU-M nude spontaneous 
mutant standard athymic mice (Taconic, Hudson, NY) (n 
= 10 per cohort) were intradermally injected with 1x106 
melanoma cells (WM164, C8161, UM001, UM004) into 
right flanks in 30µl of saline. Lesions were pre-established 
for 10 days. Then, experimental animal were treated via 
IP injection of 100 l of LDX in saline at 15 mg/kg dose, 
whereas 3 cohorts of control mice received saline. Dose 
and rout of administration were adopted from prior in vivo 
studies with first generation CXCR1 inhibitor, Reparixin 
[40]. 
Tumor measurements
Progression of the intradermal lesions was 
monitored by measuring 3 longest diameters using digital 
calipers. Tumor volume was calculated by multiplication 
of width x length x height. 
Indirect immunofluorescent and Western blot 
analyses
Indirect immunofluorescent detection of antigens 
was done on paraformaldehyde fixed, Triton X-100 
permeabilized 7 µm cryo-sections or on cells plated onto 
glass chamber slides (Millipore, Billerica, MA) according 
to standard protocol. After permeabilization, slides were 
washed in PBS, blocked with 1% BSA and incubated with 
primary and secondary antibodies for 1 h each following 
counterstaining of nuclei with DAPI (Sigma, St. Louis, 
MO). Species-specific AlexaFluor488- or AlexaFluor594 - 
labeled secondary antibodies were from Thermo-Fisher 
(Thermo/Fisher, Grand Island, NY). Western blot analysis 
was done using cell and tumor lysates in RIPA buffer. All 
antibodies were used in recommended dilutions (provided 
in Supplementary Materials and Methods). 
Quantitation of microvessel density (MVD)
Individual sections of LDX-treated and untreated 
tumor lesions were stained with CD31-specific antibodies 
(Thermo/Fisher, Grand Island, NY). Microvessel density 
was determined on ten random hotspots by direct counting 
of CD31-positive blood vessels as described previously 
[41]. Percent inhibition Thermo/Fisher, Grand Island, NY 
between MVD of untreated and treated lesions. MVD 
was assessed in control and LDX-treated lesions of a 
compatible size.
RT-PCR
Total RNA was isolated from cultured melanoma 
cells using RNeasy total RNA extraction kit (Qiagen, 
Valencia, CA). First-strand DNA was synthesized 
using Super Script III reverse transcriptase (Invitrogen, 
Grand Island, NY). Chemokines and receptors were 
amplified using the following primers: CXCL1 forward 
5’- AGGGAATTCACCCCAAGAAC-3’ and reverse 
5’- TGGATTTGTCACTGTTCAGCA -3’; CXCL8 
forward 5’-ATGACTTCCAAGCTGGCC-3’ and reverse 
5’-CAGACAGAGCTCTCTTCC-3’; CXCR1 forward 5’- 
AGGGGCCACACCAACCTTCTG -3’ and reverse 5’- 
AGTGCCTGCCTCAATGTCTCCA 3’; CXCR2 forward 
5’- CAGTTACAGCTCTACCCTGCC -3’ and reverse 
5’-CCAGGAGCAAGGACAGACCCC- 3’. Amplification 
of β-Actin was used as a loading control.
Quantitation of immunostainings
To quantify cells detected in lesions by the 
indirect immunofluorescence, 5 consecutive 7 µm cryo-
sections were taken from individual samples with 100 
µm intervals. All generated sections were stained with 
respective antibodies and images of 3 random microscopic 
fields were taken. Fluorescent antibody-labeled cells were 
quantified on images using ImagePro software. Data for 
each antigen was averaged and standard deviations were 
determined. 
Statistical analysis
Comparison of two samples (control vs treatment) 
was done using paired 2-tailed t-test. In tumor growth 
experiments, difference between LDX-treated and control 
tumors was considered statistically significant when 
significant difference was observed at 3 consecutive time 
points. p < 0.05 was considered statistically significant.
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